Clinical outcome of patients with Ewing sarcoma family of tumors of bone in Japan: The Japanese musculoskeletal oncology group cooperative study

Hideto Obata, Takafumi Ueda, Akira Kawai, Takeshi Ishii, Toshihumi Ozaki, Satoshi Abe, Kazuhiro Tanaka, Hiroyuki Tsuchiya, Akihiko Matsumine, Hiroo Yabe

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

BACKGROUND. Ewing sarcoma family of tumors (ESFT) of bone is extremely rare in Japan. The objectives of the current study were to assess the clinical outcome and prognostic factors of patients with ESFT of bone in Japan and to compare them between Euro-American and Japanese populations. METHODS. The authors conducted a retrospective analysis of 243 patients who were treated for ESFT of bone in Japan between 1981 and 2003. Local therapy was surgery in 35% of patients, surgery combined with radiotherapy in 40% of patients, radiotherapy alone in 22% of patients, and no local treatment in 3% of patients. All but 3 patients received various regimens of multidrug chemotherapy. RESULTS. The median patient age was 16 years. The primary disease sites were the trunk in 53% of patients and the extremities in 47% of patients. Forty-one patients had metastases at presentation. The median follow-up was 66 months. A univariate survival analysis demonstrated that patients who had metastases at presentation, primary site in the trunk, age ≥16 years, tumor size ≥10 cm, tumor that responded poorly to induction chemotherapy, and local treatment with radiotherapy alone had a significantly worse event-free survival (EFS). A multivariate analysis further verified that the former 3 factors were significant adverse prognostic factors. Of 201 patients with localized disease, 45 patients who received current chemotherapy regimens that included ifosfamide and etoposide had a significantly better 5-year EFS rate (67.6%) compared with other patients. CONCLUSIONS. The clinical outcome of patients with localized ESFT of bone in Japan has improved markedly with the use of current chemotherapy regimens that include ifosfamide and etoposide and has become comparable to the outcomes observed in other major series of Euro-American patients. The prognostic factors are also almost identical.

Original languageEnglish
Pages (from-to)767-775
Number of pages9
JournalCancer
Volume109
Issue number4
DOIs
Publication statusPublished - Feb 15 2007

Fingerprint

Ewing's Sarcoma
Japan
Bone and Bones
Neoplasms
Ifosfamide
Radiotherapy
Etoposide
Drug Therapy
Disease-Free Survival
Neoplasm Metastasis
Induction Chemotherapy
Survival Analysis

Keywords

  • Asian Continental Ancestry Group
  • Ewing
  • Sarcoma
  • Treatment outcome

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Clinical outcome of patients with Ewing sarcoma family of tumors of bone in Japan : The Japanese musculoskeletal oncology group cooperative study. / Obata, Hideto; Ueda, Takafumi; Kawai, Akira; Ishii, Takeshi; Ozaki, Toshihumi; Abe, Satoshi; Tanaka, Kazuhiro; Tsuchiya, Hiroyuki; Matsumine, Akihiko; Yabe, Hiroo.

In: Cancer, Vol. 109, No. 4, 15.02.2007, p. 767-775.

Research output: Contribution to journalArticle

Obata, H, Ueda, T, Kawai, A, Ishii, T, Ozaki, T, Abe, S, Tanaka, K, Tsuchiya, H, Matsumine, A & Yabe, H 2007, 'Clinical outcome of patients with Ewing sarcoma family of tumors of bone in Japan: The Japanese musculoskeletal oncology group cooperative study', Cancer, vol. 109, no. 4, pp. 767-775. https://doi.org/10.1002/cncr.22481
Obata, Hideto ; Ueda, Takafumi ; Kawai, Akira ; Ishii, Takeshi ; Ozaki, Toshihumi ; Abe, Satoshi ; Tanaka, Kazuhiro ; Tsuchiya, Hiroyuki ; Matsumine, Akihiko ; Yabe, Hiroo. / Clinical outcome of patients with Ewing sarcoma family of tumors of bone in Japan : The Japanese musculoskeletal oncology group cooperative study. In: Cancer. 2007 ; Vol. 109, No. 4. pp. 767-775.
@article{984f6e78315643a0adde5b1bb15016f4,
title = "Clinical outcome of patients with Ewing sarcoma family of tumors of bone in Japan: The Japanese musculoskeletal oncology group cooperative study",
abstract = "BACKGROUND. Ewing sarcoma family of tumors (ESFT) of bone is extremely rare in Japan. The objectives of the current study were to assess the clinical outcome and prognostic factors of patients with ESFT of bone in Japan and to compare them between Euro-American and Japanese populations. METHODS. The authors conducted a retrospective analysis of 243 patients who were treated for ESFT of bone in Japan between 1981 and 2003. Local therapy was surgery in 35{\%} of patients, surgery combined with radiotherapy in 40{\%} of patients, radiotherapy alone in 22{\%} of patients, and no local treatment in 3{\%} of patients. All but 3 patients received various regimens of multidrug chemotherapy. RESULTS. The median patient age was 16 years. The primary disease sites were the trunk in 53{\%} of patients and the extremities in 47{\%} of patients. Forty-one patients had metastases at presentation. The median follow-up was 66 months. A univariate survival analysis demonstrated that patients who had metastases at presentation, primary site in the trunk, age ≥16 years, tumor size ≥10 cm, tumor that responded poorly to induction chemotherapy, and local treatment with radiotherapy alone had a significantly worse event-free survival (EFS). A multivariate analysis further verified that the former 3 factors were significant adverse prognostic factors. Of 201 patients with localized disease, 45 patients who received current chemotherapy regimens that included ifosfamide and etoposide had a significantly better 5-year EFS rate (67.6{\%}) compared with other patients. CONCLUSIONS. The clinical outcome of patients with localized ESFT of bone in Japan has improved markedly with the use of current chemotherapy regimens that include ifosfamide and etoposide and has become comparable to the outcomes observed in other major series of Euro-American patients. The prognostic factors are also almost identical.",
keywords = "Asian Continental Ancestry Group, Ewing, Sarcoma, Treatment outcome",
author = "Hideto Obata and Takafumi Ueda and Akira Kawai and Takeshi Ishii and Toshihumi Ozaki and Satoshi Abe and Kazuhiro Tanaka and Hiroyuki Tsuchiya and Akihiko Matsumine and Hiroo Yabe",
year = "2007",
month = "2",
day = "15",
doi = "10.1002/cncr.22481",
language = "English",
volume = "109",
pages = "767--775",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Clinical outcome of patients with Ewing sarcoma family of tumors of bone in Japan

T2 - The Japanese musculoskeletal oncology group cooperative study

AU - Obata, Hideto

AU - Ueda, Takafumi

AU - Kawai, Akira

AU - Ishii, Takeshi

AU - Ozaki, Toshihumi

AU - Abe, Satoshi

AU - Tanaka, Kazuhiro

AU - Tsuchiya, Hiroyuki

AU - Matsumine, Akihiko

AU - Yabe, Hiroo

PY - 2007/2/15

Y1 - 2007/2/15

N2 - BACKGROUND. Ewing sarcoma family of tumors (ESFT) of bone is extremely rare in Japan. The objectives of the current study were to assess the clinical outcome and prognostic factors of patients with ESFT of bone in Japan and to compare them between Euro-American and Japanese populations. METHODS. The authors conducted a retrospective analysis of 243 patients who were treated for ESFT of bone in Japan between 1981 and 2003. Local therapy was surgery in 35% of patients, surgery combined with radiotherapy in 40% of patients, radiotherapy alone in 22% of patients, and no local treatment in 3% of patients. All but 3 patients received various regimens of multidrug chemotherapy. RESULTS. The median patient age was 16 years. The primary disease sites were the trunk in 53% of patients and the extremities in 47% of patients. Forty-one patients had metastases at presentation. The median follow-up was 66 months. A univariate survival analysis demonstrated that patients who had metastases at presentation, primary site in the trunk, age ≥16 years, tumor size ≥10 cm, tumor that responded poorly to induction chemotherapy, and local treatment with radiotherapy alone had a significantly worse event-free survival (EFS). A multivariate analysis further verified that the former 3 factors were significant adverse prognostic factors. Of 201 patients with localized disease, 45 patients who received current chemotherapy regimens that included ifosfamide and etoposide had a significantly better 5-year EFS rate (67.6%) compared with other patients. CONCLUSIONS. The clinical outcome of patients with localized ESFT of bone in Japan has improved markedly with the use of current chemotherapy regimens that include ifosfamide and etoposide and has become comparable to the outcomes observed in other major series of Euro-American patients. The prognostic factors are also almost identical.

AB - BACKGROUND. Ewing sarcoma family of tumors (ESFT) of bone is extremely rare in Japan. The objectives of the current study were to assess the clinical outcome and prognostic factors of patients with ESFT of bone in Japan and to compare them between Euro-American and Japanese populations. METHODS. The authors conducted a retrospective analysis of 243 patients who were treated for ESFT of bone in Japan between 1981 and 2003. Local therapy was surgery in 35% of patients, surgery combined with radiotherapy in 40% of patients, radiotherapy alone in 22% of patients, and no local treatment in 3% of patients. All but 3 patients received various regimens of multidrug chemotherapy. RESULTS. The median patient age was 16 years. The primary disease sites were the trunk in 53% of patients and the extremities in 47% of patients. Forty-one patients had metastases at presentation. The median follow-up was 66 months. A univariate survival analysis demonstrated that patients who had metastases at presentation, primary site in the trunk, age ≥16 years, tumor size ≥10 cm, tumor that responded poorly to induction chemotherapy, and local treatment with radiotherapy alone had a significantly worse event-free survival (EFS). A multivariate analysis further verified that the former 3 factors were significant adverse prognostic factors. Of 201 patients with localized disease, 45 patients who received current chemotherapy regimens that included ifosfamide and etoposide had a significantly better 5-year EFS rate (67.6%) compared with other patients. CONCLUSIONS. The clinical outcome of patients with localized ESFT of bone in Japan has improved markedly with the use of current chemotherapy regimens that include ifosfamide and etoposide and has become comparable to the outcomes observed in other major series of Euro-American patients. The prognostic factors are also almost identical.

KW - Asian Continental Ancestry Group

KW - Ewing

KW - Sarcoma

KW - Treatment outcome

UR - http://www.scopus.com/inward/record.url?scp=33846921311&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846921311&partnerID=8YFLogxK

U2 - 10.1002/cncr.22481

DO - 10.1002/cncr.22481

M3 - Article

C2 - 17238190

AN - SCOPUS:33846921311

VL - 109

SP - 767

EP - 775

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 4

ER -